评估一种ICD-10代码方法,用于估计在美国发生过量服用西拉导致的死亡
1Department of Psychiatry, University of California, San Diego, United States.
Drug and alcohol dependence
|July 15, 2025
概括
兽医镇静剂西拉 (xylazine) 越来越多地与美国过量死亡有关. 使用ICD-10代码T42.7和T46.5提供了最新的估计,显示到2024年初,西拉死亡人数翻了一番,种族差异扩大.
科学领域:
- 公共卫生 公共卫生
- 毒理学 毒理学 毒理学
- 流行病学 流行病学
背景情况:
- 在美国过量服用死亡中,西拉的患病率从2018年至2021年增加.
- 由于没有专门的ICD-10代码,因此存在有限的最新估计.
- 总体代码可能代表新出现的物质,但对于xylazine,这一点尚未得到证实.
研究的目的:
- 确定ICD-10代码T42.7和T46.5是否已成为与克西拉有关的过量死亡的实际指标.
- 提供截至2024年初的新拉涉及过量死亡的最新估计.
- 通过人口统计和物质共同参与来分析拉相关死亡的趋势.
主要方法:
- 使用T42.7或T46.5的CDC WONDER数据与2018-2022年的国家 (NVSS) 和州级 (SUDORS) 数据进行了比较.
- 利用CDC的WONDER方法,估计到2024年第一季度与克西拉有关的死亡人数.
- 分析了按地理位置,种族/种族,物质共同参与和人口统计数据的趋势.
主要成果:
- 在2021年,CDC WONDER和NVSS估计与克西拉相关的死亡人数之间的一致性很高.
- 在州一级,CDC WONDER和SUDORS估计之间的相关性很强 (0.97).
- 据估计,2021年至2024年第一季度,与化种族不平等有关的死亡人数翻了一番.
结论:
- ICD-10代码T42.7和T46.5很可能作为实际的鉴定器,用于与克西拉有关的过量死亡.
- 这种编码方法可以获得有关西拉患病率上升的最新数据.
- 调查结果突出显示,到2024年,与克西拉相关的死亡事件中种族差异正在恶化.
更多相关视频
相关概念视频
Prevention of Further Absorption of Poison
930
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
930
Anticholinesterase Agents: Poisoning and Treatment
1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K
Pharmacovigilance
996
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
996
Drug Regulation
1.9K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.9K
Parenteral Anesthetics: Overview
202
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
202
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
144
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
144


